2 results
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMOPending
The primary objective of the study is to evaluate the efficacy of dupilumab on the lung function in patients with ABPA.The secondary objectives of the study are:• To evaluate the effects of dupilumab on exacerbations in patients with ABPA • To…